NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1390-1401

  Lawrenson, Kate ^a   Grun, Barbara ^b   Lee, Nathan ^a   Mhawech Fauceglia, Paulette ^a   Kan, Jenny ^c   Swenson, Steve ^a   Lin, Yvonne G ^a   Pejovic, Tanja ^c   Millstein, Joshua ^a   Gayther, Simon A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

BNP; Cancer associated fibroblast; Fibroblast; Microarray; Microenvironment; NPPB; Ovarian cancer; Stroma; Xenograft

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TUMOR MARKER; 5-NITRO-2-(3-PHENYLPROPYLAMINO)BENZOIC ACID; NITROBENZOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER STAGING; CARCINOGENICITY; CELL MIGRATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; NPPB GENE; OVARY CARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SECRETION; STROMA CELL; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; MESENCHYMAL STROMA CELL; MOUSE; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NITROBENZOATES; OVARIAN NEOPLASMS;

EID: 84922237585     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29092     Document Type: Article

References (31)

1. http://seer.cancer.gov.
2. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. Labiche A, Heutte N, Herlin P, et al. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int J Gynecol Cancer 2010;20:28-33.
4. Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011;52:1787-94.
5. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
6. Müerköster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004;64:1331-7.
7. Singh RR, Kunkalla K, Qu C, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011;30:4874-86.
8. Yang G, Rosen DG, Zhang Z, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 2006;103:16472-7.
9. Cai J, Tang H, Xu L, et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 2012;33:20-9.
10. R S, Morikawa T, Shee K, et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
11. Kidd S, Spaeth E, Watson K, et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012;7:e30563.
12. Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-5.
13. Akahane T, Hirasawa A, Tsuda H, et al. The origin of stroma surrounding epithelial ovarian cancer cells. Int J Gynecol Pathol 2013;32:26-30.
14. Jazedje T, Perin PM, Czeresnia CE, et al. Human fallopian tube: a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures. J Transl Med 2009;7:46.
15. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009;4:e4992.
16. Shangguan L, Ti X, Krause U, et al. Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their pro-tumor effects. Stem Cells 2012.
17. McLean K, Gong Y, Choi Y, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011;121:3206-19.
18. Li NF, Wilbanks G, Balkwill F, et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest 2004;84:923-31.
19. Lawrenson K, Grun B, Benjamin E, et al. Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia 2010;12:317-25.
20. Korch C, Spillman MA, Jackson TA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 2012;127:241-8.
21. Rasband WS. ImageJ. Bethesda, MD: U. S. National Institutes of Health, 1997-2012. Available at: http://imagej.nih.gov/ij/.
22. Dunning MJ, Smith ML, Ritchie ME, et al. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007;23:2183-4.
23. Millstein J, Volfson D, Lamb JR, Dai H, Friend SH, Schadt EE, Bergh J. Permutation-based yet computationally parsimonious FDR point and confidence interval estimators. Joint Statistical Meetings 2010. 4184-97.
24. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
25. Wysham WZ, Mhawech-Fauceglia P, Li H, et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012;7:e30042.
26. McCullough PA. B-type natriuretic peptides. A diagnostic breakthrough in heart failure. Minerva Cardioangiol 2003;51:121-9.
27. Aujollet N, Meyer M, Cailliod R, et al. High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer? Clin Lung Cancer 2010;11:341-5.
28. Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J 2011;278:1316-32.
29. Göcze PM, Szabò DG, Than GN, et al. Placental protein 4 as a possible tumor marker in ovarian tumors. Gynecol Obstet Invest 1991;32:107-11.
30. Lenhard M, Tsvilina A, Schumacher L, et al. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer. BMC Cancer 2012;12:2.
31. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.